TY - JOUR
T1 - Myelodysplastic syndromes
AU - Greenberg, Peter L.
AU - Attar, Eyal
AU - Battiwalla, Minoo
AU - Bennett, John M.
AU - Bloomfield, Clara D.
AU - DeCastro, Carlos M.
AU - Deeg, Joachim
AU - Erba, Harry P.
AU - Foran, James M.
AU - Garcia-Manero, Guillermo
AU - Gore, Steven D.
AU - Head, David
AU - Maness, Lori J.
AU - Millenson, Michael
AU - Nimer, Stephen D.
AU - O'Donnell, Margaret R.
AU - Saba, Hussain I.
AU - Shami, Paul J.
AU - Spiers, Kathy
AU - Stone, Richard M.
AU - Tallman, Martin S.
AU - Westervelt, Peter
PY - 2008/10
Y1 - 2008/10
N2 - These suggested practice guidelines are based on extensive evaluation of reviewed risk-based data and indicate useful current approaches for managing patients with MDS. The FDA recently approved 4 drugs for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic, abnormalities; azacytidine and decitabine for treating higher-risk or nonresponsive MDS patients; and deferasirox for iron chelation of MDS patients with iron overload. However, because a substantial proportion of MDS patient subsets lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines in managing thrombocytopenia in MDS requires fiirther evaluation. In addition, further determination of the effects of these therapeutic interventions on patient QOL is important.97,100,101,109,110 Progress toward improving management of MDS has occurred over the past few years and more advances are anticipated using these guidelines as a framework for coordinating comparative clinical trials.
AB - These suggested practice guidelines are based on extensive evaluation of reviewed risk-based data and indicate useful current approaches for managing patients with MDS. The FDA recently approved 4 drugs for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic, abnormalities; azacytidine and decitabine for treating higher-risk or nonresponsive MDS patients; and deferasirox for iron chelation of MDS patients with iron overload. However, because a substantial proportion of MDS patient subsets lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines in managing thrombocytopenia in MDS requires fiirther evaluation. In addition, further determination of the effects of these therapeutic interventions on patient QOL is important.97,100,101,109,110 Progress toward improving management of MDS has occurred over the past few years and more advances are anticipated using these guidelines as a framework for coordinating comparative clinical trials.
KW - Chronic myelomonocytic leukemia
KW - Cytopenias
KW - Myelodysplastic syndromes
KW - NCCN clinical practice guidelines
KW - Refractory anemia
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=56049098183&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2008.0069
DO - 10.6004/jnccn.2008.0069
M3 - Review article
C2 - 18926100
AN - SCOPUS:56049098183
SN - 1540-1405
VL - 6
SP - 902
EP - 925
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 9
ER -